Skip to main content
ACRS logo

ACRS · Aclaris Therapeutics, Inc.

Track ACRS — free
$3.48 -0.02 (-0.57%)
Market Cap
$555.14M
Shares
158.61M
Volume · Nov 19 1.89M Avg daily vol (3M) 3.05M

Price & Indicators

 

Key stats

Close
$3.50
Open
$3.53
Day range
$3.44–3.62
52-week closing range
$2.41–6.54
Average volume, 30 days
2.9M
Short interest
11.6M · 7.3% of shares · 4.0 days
Short volume, last session
57%
Last earnings
Oct 27, 2026
Latest filing
10-Q · Nov 5
Price history
Jan 2020 to Nov 2026

Up next

Apr 17, 2029 Est · unconfirmed · in 126 wks
call held May 7, 2024

Latest documents

2026
Nov 16
Investor event
Oral lichen planus study starts; next-generation program nears filing

Clarice Therapeutics initiated an oral lichen planus study targeting 35 to 40 patients, with a 16-week endpoint, and plans to file its next-generation oral program this quarter.

5 source passages
It is my pleasure to have a five-side chat with our company, Clarice Therapeutics. The goal is to enroll somewhere between 35 and 40 patients. We have a 16-week endpoint. With an interim analysis after about 60% of patients have reached the week 16 endpoint. It's just about pressing the button and filing that this quarter. Open the document at this passage
Nov 16
Current report 8-K
Bosakitug trial fails while modzatinib lichen planus study begins

Aclaris Therapeutics, Inc. reported that the Phase 2 ADMIRATION trial of bosakitug (ATI-045) did not achieve primary or secondary endpoints at Week 24; it also began the Phase 2b ALPHA trial of modzatinib (ATI-2138) in lichen planus.

Regulation FD disclosure, Other events
3 source passages
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced top line results from the Phase 2 ADMIRATION trial that evaluated the efficacy and safety of bosakitug (ATI-045), a humanized anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, in patients with moderate-to-severe atopic dermatitis. The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 24 Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced initiation of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial of modzatinib (ATI-2138) in patients with moderate-to-severe lichen planus (LP); the first cohort to be enrolled will be patients with oral erosive lichen planus (OLP). Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
ATI-052 delivers positive Phase 1b results in two diseases

ATI-052 produced positive Phase 1b results in atopic dermatitis and asthma, while Aclaris Therapeutics reported a $59.8 million net loss for the nine months ended September 30, 2026.

Revenue $1.48M ▼ 55.1% Net loss $18.51M Diluted EPS -$0.12
Read from the MD&A section
2 source passages
In October 2026, we announced positive primary analysis results from two randomized, double-blind, placebo-controlled Phase 1b proof-of-concept (“POC”) trials of ATI-052 in patients with atopic dermatitis (“AD”) and asthma. Our net loss was $59.8 million for the nine months ended September 30, 2026 Open the document at this passage
Nov 5
Current report 8-K
Q3 2026 net loss $18.5 million, up from $14.6 million

Aclaris reported a third-quarter 2026 net loss of $18.5 million, versus $14.6 million a year earlier, with $204.6 million in cash and marketable securities at September 30, 2026. October 2026 sales of stock and pre-funded warrants raised $50.0 million gross, and cash is expected to fund operations through the first half of 2029. Phase 1b trials of ATI-052 showed positive primary results in atopic dermatitis and asthma.

Financial results
5 source passages
Net loss was $18.5 million for the third quarter of 2026 compared to $14.6 million for the third quarter of 2025. As of September 30, 2026, Aclaris had cash, cash equivalents and marketable securities of $204.6 million compared to $151.4 million as of December 31, 2025. During October 2026, the Company sold 7.8 million shares of its common stock and issued pre-funded warrants to purchase 6.5 million shares of common stock for aggregate gross proceeds of $50.0 million, pursuant to the Company's underwriting agreement with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co. the Company believes that its cash, cash equivalents and marketable securities will be sufficient to fund its operations through the first half of 2029, without giving effect to any potential business development transactions or additional financing activities. Positive Primary Analysis Results Showed Rapid Improvement in Airway Inflammation and Lung Function in Phase 1b POC Trials of ATI-052 in Asthma Open the document at this passage
Oct 27
Current report 8-K
Underwritten Offering of 7,785,714 Shares Priced at $3.50 Per Share

Aclaris Therapeutics entered into an underwriting agreement on October 27, 2026 to sell 7,785,714 shares of common stock and pre-funded warrants to purchase 6,500,000 shares. The offering price is $3.50 per share and $3.49999 per Pre-Funded Warrant. The company estimates net proceeds of approximately $46.7 million, with closing expected on October 28, 2026.

Entered into a material agreement Read from the first part of this long document
5 source passages
On October 27, 2026, Aclaris Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) to issue and sell 7,785,714 shares of common stock of the Company, par value $0.00001 per share (“Common Stock”) and pre-funded warrants to purchase 6,500,000 shares of Common Stock (the “Pre-Funded Warrants”) The offering price is $3.50 per share of Common Stock and $3.49999 per Pre-Funded Warrant. The Company estimates that the net proceeds from the Offering will be approximately $46.7 million, after deducting underwriting discounts and commissions and estimated offering expenses. The closing of the Offering is expected to occur on October 28, 2026, subject to customary closing conditions. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$6.40M
Trailing 12 months
Net income (TTM)
−$79.63M
Trailing 12 months
Revenue growth YoY
-55.1%
Year over year
Operating margin
-1,414.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-13.6%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$20.39M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+21.9%
Year over year · more shares
Price change (1Y)
+42.3%
Trailing year
Short interest
7.3%
Latest settlement · 4.0 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 28.4 · fear Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −23%
below
Price vs 50-day avg −18%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 26%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −9%
trailing
6-month return −19%
trailing
YTD return +16%
this year
Relative strength −14%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+13% holders QoQ · +39 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.30% of shares out · ▼ -23.0% MoM · 4.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
169 holders — near 3-yr high, broad support
Squeeze score 65
elevated · 0–100
Fundamentals
Strong
Gross margin 193%
EPS growth +69%
Y/Y
Free cash flow $-47.2M
Balance sheet $20.0M
net cash
Quant / Vol
risk profile
Very High
Volatility 99%
annualized · 1-yr
Max drawdown −50%
past year
ATR 8.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 4 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−23% Bearish
Price vs 50-day avg
−18% Bearish
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
26% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $4 › 200d $5 — 200d above 50d
Institutional flow Accumulating
+13% holders QoQ · +39 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
7.30% of shares out · ▼ -23.0% MoM · 4.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
169 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $2 Now $4 · 26% Range high $7
vs 200-day avg -23% vs 50-day avg -18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
FeNO reduction at day 29 40% day 29 —
mean absolute reduction in fractional exhaled nitric oxide (FeNO) 59% day 15 —
placebo adjusted and absolute improvement in FEV1 200 day 15 —
placebo-adjusted EASI-50 78% week 8 —
placebo-adjusted mean change in EASI score 45% week 8 —
placebo-adjusted mean improvement in itch (PP-NRS) 43% week 8 —
% PP-NRS Reduction 38% D57 —
% Reduction from Baseline in EASI 58% D57 —
% Reduction in FeNO 59% D15 —
78% 78% baseline —
ATI-052 (FEV1 <80% at BL) 350 Day 15 —
EASI-50 78% D57 —
FeNO normalization 58% day 15 —
FeNO reductions in the eosinophil <300 subgroup (T2-low) 58% day 15 —
FeNO reductions in the eosinophil ≥300 subgroup (T2-high) 60% day 15 —
Increase in FEV1 (FEV1 <80% at BL) 350 D15 —
Mean change in EASI score in the active arm 58% day 57 —
Mean change in EASI score in the placebo arm 13% day 57 —
Mean decrease from baseline in FEV1 in the placebo arm 140 day 15 —
Mean improvement in itch (PP-NRS) 40% week 4 —
Mean reduction from baseline in FeNO 40% day 29 —
Mean reduction from baseline in FeNO in the placebo arm 15% day 15 —
Mean worsening in itch (PP-NRS) in the placebo arm 5% day 57 —
Normalization in the lesional skin proteome 95% week 8 —
Overall = 78% 78% Week 8 —
Patients with mild-to-moderate asthma 16 Phase 1b POC Trial in Asthma —
Patients with severe AD 14 Phase 1b POC Trial in AD —
Patients with severe disease at baseline 78% baseline —
Pbo-adjusted Mean pre-BD FEV1 change from baseline 200 Day 15 —
Placebo (FEV1 <80% at BL) -140 Day 15 —
placebo adjusted and absolute mean improvement in FEV1 200 day 15 —
Placebo-adjusted and absolute mean improvement in FEV1 200 day 15 —
Placebo-adjusted EASI-50 in patients with a baseline severity of vIGA 3 100% day 57 —
Placebo-adjusted EASI-50 in patients with a baseline severity of vIGA 4 71% day 57 —
Placebo-adjusted mean improvement of ≥4-points in itch (PP-NRS4) 33% day 57 —
worsening in itch (PP-NRS) 5% day 57 —
worsening of FEV1 -140 day 15 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ACRS
Aclaris Therapeutics, Inc.
this stock
$555.14M +16.3% -58.2% — 7.3%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.36B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
169
% held
87.3%
Net QoQ
+19.4M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
143
View
Short & Settlement
Short Interest Falling
Shares short
11.6M
Days to cover
4.0d
Change
-3.5M sh
View
Short Volume
Short vol %
57%
As of
Nov 19, 2026
Short Total
View
Fails to Deliver
FTD shares
4.9K
Value
$18.4K
As of
Oct 26, 2026
View
Off-Exchange
Off-exchange %
38.4%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$7.8M
Net income (FY)
$-64.9M
EPS diluted
$-0.53
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 16, 2026
This year
25

Clarice Therapeutics initiated an oral lichen planus study targeting 35 to 40 patients, with a 16-week endpoint, and plans to file its next-generation oral program this quarter.

View
Proposed Sales
Value
$31.7K
Shares
6.0K
Filed
Oct 23, 2023
View
Exempt Offerings
Offering
$80.0M
Filed
Dec 4, 2024
View
Earnings & Events
Webcasts
Last webcast
Nov 16, 2026
View
Investor Relations
Latest news
Aclaris Therapeutics Initiates Ph…
Published
Nov 16, 2026
View

Performance

5D 20D 120D MTD YTD
ACRS -12.5% -8.6% -19.4% -11.8% +16.3%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -7.1% -2.3% -13.7% -6.6% +11.3%
Key facts CIK 1557746 CUSIP 00461U105 13F (30d) 182 filings 159 filers Visit website Investor relations